Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
2021 · The Lancet · 288 citations
https://doi.org/10.1016/s0140-6736(21)01122-3
M
Michel Farnier
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
382
Papers
13.9K
Citations
51
h-index
155
i10-index
Michel Farnier is an academic researcher from Université de Bourgogne. The author has contributed to research in topics: Lipoproteins and Cardiovascular Health & Diabetes, Cardiovascular Risks, and Lipoproteins & Cancer, Lipids, and Metabolism. The author has an h-index of 51, co-authored 325 publications.
ORCID: 0000-0002-0349-7978Papers by this author
worksEfficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
2015 · Atherosclerosis · 186 citations
https://doi.org/10.1016/j.atherosclerosis.2015.11.010
Residual macrovascular risk in 2013: what have we learned?
2014 · Cardiovascular Diabetology · 169 citations
https://doi.org/10.1186/1475-2840-13-26
PCSK9: From discovery to therapeutic applications
2014 · Archives of cardiovascular diseases · 99 citations
https://doi.org/10.1016/j.acvd.2013.10.007
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
2016 · European Heart Journal Supplements · 96 citations
https://doi.org/10.1093/eurheartj/suw009
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
2023 · The Lancet · 71 citations
https://doi.org/10.1016/s0140-6736(23)01842-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat